GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock Based Compensation: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
74 GF Score
Price ₹2,463.40
GF Value ₹2,627.22
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals Stock Based Compensation?

GlaxoSmithKline Pharmaceuticals NSE:GLAXO +1.77% 74 Stock Based Compensation is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:GLAXO with a GF Score™ of 74/100 and a GF Value™ of ₹2,627.22 (Fairly Valued). The stock has 1 warning sign investors should review.

GlaxoSmithKline Pharmaceuticals's Stock Based Compensation for the three months ended in Mar. 2026 was ₹0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

GlaxoSmithKline Pharmaceuticals Stock Based Compensation Related Terms

GlaxoSmithKline Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals Stock Based Compensation Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GlaxoSmithKline Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:GLAXO
74GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

What does a Stock Based Compensation of ₹0 Mil mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Stock Based Compensation of ₹0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors.
Is GlaxoSmithKline Pharmaceuticals' Stock Based Compensation too high?
GlaxoSmithKline Pharmaceuticals' current Stock Based Compensation is ₹0 Mil. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Stock Based Compensation compare to LLY and JNJ?
GlaxoSmithKline Pharmaceuticals' Stock Based Compensation of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors. GlaxoSmithKline Pharmaceuticals's current Stock Based Compensation is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,627.22, compared to a current price of ₹2,463.40 — trading 6.2% below its estimated fair value. The current Stock Based Compensation is ₹0 Mil. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Stock Based Compensation is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued. The current stock price of ₹2,463.40 is trading 6.2% below its estimated GF Value™ of ₹2,627.22. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLAXO:

  • Stock Based Compensation: ₹0 Mil
  • GF Value™: ₹2,627.22 vs. price of ₹2,463.40 (6.2% below fair value)
  • GF Score™: 74/100 with 1 warning sign

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
74GF Score

Get the complete analysis for NSE:GLAXO

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,463.40
Price
₹2,627.22
GF Value